Reference Detail

Ref Type
PMID
Authors Andres Forero-Torres, Paul M. Barr, Catherine S. Magid Diefenbach, Taimur Sher, Richard Schaub, Li Zhou, Jennifer Pulini, Lance Leopold, Matthew A. Spear, Moshe Talpaz, Tycel Jovelle Phillips
Title A phase 1 study of INCB040093, a PI3K? inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Journal J Clin Oncol
Vol
Issue
Date
URL http://meetinglibrary.asco.org/content/146209-156
Abstract Text J Clin Oncol 33, 2015 (suppl; abstr 8558)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Hodgkin's lymphoma not applicable Itacitinib + INCB040093 Phase I Actionable In a Phase I trial, INCB040093 and INCB039110 combination treatment resulted in complete response in 22% (2/9) of Hodgkin's lymphoma patients, with an objective response rate of 67% (J Clin Oncol 33, 2015 (suppl; abstr 8558)). detail...
Unknown unknown Hodgkin's lymphoma not applicable INCB040093 Phase I Actionable In a Phase I trial, INCB040093 treatment resulted in complete response in 17% (1/6) of Hodgkin's lymphoma patients, with an objective response rate of 50% (J Clin Oncol 33, 2015 (suppl; abstr 8558)). detail...